Answers are grounded in this paper and cite their sources.
Background HDFN is a significant cause of newborn mortality. This study aimed to identify the frequency of primary alloantibodies responsible for HDFN and evaluate associated clinical outcomes at a tertiary care hospital in Riyadh, Saudi Arabia. Methods This retrospective study analyzed 4,340 newborns. Direct antiglobulin test (DAT)-positive cases were evaluated. Lui freeze-thaw elution and acid elution procedures were used to detect specific ABO and Rh incompatibilities, respectively. Lui freeze-thaw elution was used for ABO antibody detection due to the labile nature of anti-A/anti-B binding, while acid elution was used for Rh and other non-ABO antibodies due to its higher sensitivity for IgG-mediated sensitization. Clinical outcomes including hyperbilirubinemia, Neonatal Intensive Care Unit (NICU) admission, and red blood cell (RBC) transfusions were evaluated. Results Out of 4,340 newborns, 267 (6.1%) tested DAT-positive. Among these, ABO incompatibility was the most frequent finding (76%, n = 204), primarily blood type B antibodies ( n = 106). Suspected Rh incompatibility accounted for 23.5% ( n = 63), with confirmed Rh antibody-mediated cases comprising 54 (20.2%) of the DAT-positive cohort; anti-D was the most frequent antibody ( n = 28). The remaining nine cases (3.4%) were classified as suspected Rh incompatibility with negative eluate. Clinically significant non-ABO antibodies, including anti-E ( n = 7) and anti-c ( n = 5), were also identified. Hyperbilirubinemia was the main clinical complication, affecting 44% of the DAT-positive cohort. The background rate of hyperbilirubinemia in the DAT-negative cohort was not systematically extractable; therefore, the clinical significance of the 44% rate cannot be fully determined and should be interpreted with caution. Despite this, clinical outcomes were generally mild: 61% of infants did not require NICU admission, and only 4.1% of DAT-positive newborns ( n = 11) required RBC transfusions. Conclusion ABO incompatibility was the main cause of HDFN at KFMC, generally resulting in favorable clinical outcomes. Future studies should evaluate whether a maternal-targeted selective DAT screening strategy, paired with comprehensive prenatal antibody profiling, could optimize resources while maintaining safety. However, this is a hypothesis-generating proposition based on our single-center data; direct comparative studies evaluating universal vs. selective screening strategies are needed before any policy changes are implemented. Future multi-center studies are recommended to confirm these findings in the Kingdom.
No takes yet. Share an insight, caveat, or question.
Alfalah et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: